A phase I trial of trimetrexate (NSC352122) on a daily x 5 schedule in patients with refractory adult leukemia.

Abstract

Seven adult patients with refractory acute leukemia were administered trimetrexate (TMTX), a non-classical folate antagonist, in a phase I trial. TMTX was administered as an intravenous bolus for five consecutive days at doses of 9-12 mg/m2 based on marrow response. The maximum tolerated dose was 12 mg/m2. Hepatotoxicity was the dose-limiting toxicity. Initial dosage reductions in patients with liver disease and/or low protein concentrations may be necessary since TMTX is significantly protein bound and cleared primarily by hepatic metabolism. The recommended phase II dose on this dosing schedule is 9 mg/m2.

• Authors: G Rodriguez, T D Brown, F M Balis, J B Craig, C A Denham, J G Kuhn, K Havlin, D D Von Hoff
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 4 Issue 2 Pg. 163-6 (Apr 1993) ISSN: 0959-4973 [Print] England
• PMID: 8490194 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Trimetrexate

Topics

• Adult
• Chromatography, High Pressure Liquid
• Drug Resistance
• Female
• Half-Life
• Humans
• Leukemia (drug therapy)
• Liver (drug effects)
• Male
• Middle Aged
• Trimetrexate (adverse effects, pharmacokinetics, therapeutic use)